Maryam Fouladi, MD, MSc
Title
Medical Director, Neuro-Oncology
Appointment
Associate Professor, Division of Hematology / Oncology, University of Cincinnati College of Medicine
Email
maryam.fouladi@cchmc.org
Phone
513-636-4266
Fax
513-636-3549
Credentials
BS: Human Biology, University of Toronto, Toronto, Canada, 1987.
MD: University of Toronto, Toronto, Canada, 1991.
MSc: Institute of Medical Science, University of Toronto, Toronto, Canada, 2002.
Publications, Most Recent
Shih C, Hale GA, Gronewold L, Tong X, Gilger EA, Srivastava DK, Kun LE, Gajjar A, Fouladi M. High-Dose Chemotherapy with Autologous Stem Cell Rescue for Children with Recurrent Malignant Brain Tumors. Cancer; 2008.
Fouladi M, Nicholson S, Zhou T, Laningham F, Helton K, et al. A Phase II Study of the Farnesyl Transferase Inhibitor, Tipifarnib, in Children with Recurrent or Progressive High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma: A Children’s Oncology Group Study. Cancer; 107(9):2291-2297, 2007.
Fouladi M, Laningham F, Wu J, O’Shaughnessy M, Molina K, Broniscer A, Spunt SL, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL. Phase I Study of Everolimus (RAD001) in Pediatric Patients with Refractory Solid Tumors. J Clin Oncol; 25(30):4806-12, 2007.
Morris B, Gajjar A, Okuma, J, Yutaka Y, Wallace D, Kun L, Merchant T, Fouladi M, Broniscer A, Robison L, Hudson M. Survival and Late Mortality in Long-term Survivors of Pediatric Central Nervous System Tumors. J Clin Oncol; 25(12):2535-2541.
Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicenter trial. Lancet Oncology; 813-820, 2006.
Fouladi M, Blaney S, Young Poussaint T, Freeman B, McLendon R, Fuller C, Adesina A, Hancock M, Danks M, Ivy P, Stewart C, Gajjar A. A Phase II study of oxaliplatin in children with recurrent or refactory medulloblastoma (MB), supratentorial primitive neuroectodermal tumors (SPNET) and atypical teratoid rhabdoid tumors (ATRT): A Pediatric Brain Tumor Consortium Study. Cancer; 107:2291-2297, 2006.
Fouladi M. Histone deacetylase inhibitors. Cancer Invest; (5):521-7, 2006.
Merchant T, Fouladi M. Ependymoma: New therapeutic approaches including radiation and chemotherapy. J Neuro Oncol; 3:287-99, 2006.
Broniscer A, Laningham FH, Kocack M, Krasin MJ, Fouladi M, Merchant TE, Kun LE, Boyett JM, Gajjar A. Intratumoral hemorrhage in children with newly diagnosed, diffuse brainstem glioma. Cancer; 106(6):1364-1371, 2006.
Fouladi M, Furman WL, Chin T, Freeman B, Stewart CF, Krailo M, Houghton PJ, Wright J, Adamson P, Blaney SC. A Phase I trial and pharmacokinetic study of depsipeptide in pediatric patients with refractory solid tumors: A Children’s Oncology Group Study. J Clin Oncol; 24(22):3678-85, 2006.
Fuller C, Fouladi M, Gajjar A, Dalton J, Sanford RA, Helton K. Chromosomes 17 abnormalities in Pediatric Neuroblastic Tumor with Abundant Neuropil and True Rosettes. Am J Clin Pathol; 126(2):1-7, 2006.
Fuller C, Helton K, Dalton J, Fouladi M, Kun L, Burger P. Polar spongioblastoma of the spinal cord: A case report. Pediatr Dev Pathol; 9(1):75-80, 2006.
Broniscer A, Chintagumpala M, Fouladi M, Krasin MJ, Kocak M, Bowers DC, Iacono LC, Merchant TE, Stewart CF, Houghton PJ, Kun LE, Ledet L, Gajjar A. Temozolomide After Radiotherapy for Newly Diagnosed High-Grade Glioma and Unfavorable Low-Grade Glioma in Children. J Neuro Oncol; 76 (3):313-319, 2006.
Graham V, Tucker C, Creech J, Favours E, Billups C, Liu T, Fouladi M, Freeman B, Stewart C, Houghton PJ. Evaluation of the antitumor efficacy, pharmacokinetics and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res; 1:223-34, 2006.
Bai F, Freeman B, Fraga C, Fouladi M, Stewart C. Determination of Lapatinib (GW572016) In Human plasma by liquid chromatography electrospray tandem mass spectrometry (LC ESI-MS/MS). Biomed Life Sci; 831:169-75, 2005.
Fouladi M, Gilger E, Kocak M, Wallace D, Buchanan G, Reeves C, Robbins N, Merchant T, Kun LE, Khan R, Gajjar A, Mulhern R. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol; 28: 7152-60, 2005.
Hinds P, Drew D, Oakes L, Fouladi M, Spunt S, Welborn D, Furman W. End-of-life care preferences of pediatric patients with cancer. J Clin Oncol; 36:9146-54, 2005.
Broniscer A, Iacono L, Chintagumpala M, Fouladi M, Wallace D, Bowers DC, Stewart C, Krasin MJ, Gajjar A. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multi-institutional study (SJHG-98). Cancer; 103:133-9, 2005.
Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Merchant TE, Krasin M, Dalton J, Hale G, Kun LE, Wallace D, Gilbertson RJ, Gajjar A. Atypical teratoid / rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-basedchemotherapy. J Clin Oncol; 23:1491-9, 2005.
Presentations, Most Recent
Invited Speaker, "New Therapies in Pediatric High Grade Gliomas." Society of Neuro-Oncology Meeting, Pediatric Educational Symposium, 2007.
Invited Key Note Speaker, "Targeted Therapy in Pediatric Neuro-Oncology: The Road Less Traveled." University of Alabama, Birmingham, Annual Neuro-Oncology Symposium.
Invited Speaker, "Novel Therapies in Pediatric Neuro-Oncology." MD Anderson Pediatric Grand Rounds, November 2006.
Invited Speaker, "Targeted Therapy in Pediatric Neuro-Oncology." Cincinnati Children's Tumor Board Conference, October 2006.
Professional Organization Memberships
- Royal College of Physicians and Surgeons of Canada
- American Society of Clinical Oncology
- Children’s Oncology Group
- Pediatric Brain Tumor Consortium
Abstracts
Fouladi M, Blaney SM, Onar A, Young-Poussaint T, Schaiquevich P, Stewart CF, Gajjar A, Dancey J, Kun LE, Boyett JM, Gilbertson RJ. A Phase I Study of Lapatinib in Pediatric Patients with recurrent or Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study. ISPNO, Chicago, IL, 2008.
Fouladi M, Park JR, Sun J, Ingle AM, Ames MM, Stewart CF, Gilbertson R, Zwiebel JA, Adamson PC, Blaney SM. A pahse I trial and pharmacokinetic (PK) study of vorinostat (SAHA) in combinsation with 13 cisretinoic acid (13cRA) in children with refractory neiroblastomas, medulloblastomas, primitive neuroctodermal tumors (PNETs), and atypical teratoid rhabdoid tumor. ASCO, Chicago, IL, 2008.
McGregor L, Spunt SL, Santana VM, Stewart CF, Ward DA, Wu J, Watkins A, Ivy SP, Furman WL, Fouladi M. Phase I Study of an Oxaliplatin–Etoposide Regimen in Pediatric Patients with Recurrent Solid Tumors. ASCO, Chicago, IL, 2008.
Gajjar A, Merchant T, Sklar C, Wallace D, Xiong Z, Shelso J, Laughton S. Endocrine outcome for children with embryonal brain tumors treated. ASCO, 2007.
Sanders RP, Onar A, Boyett JM, Broniscer A, Fouladi M, Merchant T, Gajjar A. M1 medulloblastoma should be considered high risk at any age. ASCO, 2007.
Fouladi M, Park J, Sun J, Fraga, C, Speights RA, Ames MM, Stewart CF, Gilbertson RJ, Zweibel J, Adamson PC, Blaney SM. A phase I trial of SAHA in children with refractory solid tumors: A Children’s Oncology Group Study. ASCO, 2007.
Gajjar A, Chintagumpala M, Ashley D, Broniscer A, Fouladi M, Wallace D, Merchant T, Kun L, Gilbertson R, Fuller C. Tumor histology is an important independent prognostic factor of event free survival in Average-risk (AR) and High-Risk (HR) Medulloblastoma (MB) – Results from a prospective collaborative trial (SJMB96). ISPNO, 2006.
Palmer SL, O’Grady J, Wallace D, Broniscer A, Fouladi M, Smeltzer M, Gajjar A. Parental education and race as covariates to estimate pre-morbid intellect for children diagnosed with medulloblastoma. ISPNO, 2006.
Laughton S, Merchant T, Broniscer A, Fouladi M, Kun LE, Gajjar A. Endocrine outcomes for children with medulloblastoma treated with craniospinal and conformal primary site irradiation on the SJMB96 Trial. ISPNO, 2006.
Fouladi M, Blaney S, Young-Poussaint T, Freeman B, McLendon R, Fuller C, Adesina A, Hancok M, Remack J, Hunt D, Danks M, Ivy P, Stewart C, Kun L, Gajjar A. A Phase II study of oxaliplatin in children with recurrent or refactory medulloblastoma (MB), supratentorial primitive neuroectodermal tumors (SPNET) and atypical teratoid rhabdoid tumors (ATRT): A pediatric brain tumor consortium study. ISPNO, 2006.
Fouladi M, Chintagumpala M, Ashley D, Kellie S, Broniscer A, Merchant T, Kun LE, Stewart C, Wallace D, Gajjar A. Role of amifostine as a cytoprotectant in children > 3 years with average risk (AR) medulloblastoma (MB) treated with craniospinal irradiation (CSI) and 4 courses of cisplatin (CDDP) - based high dose chemotherapy. ASCO, 2006.
Fouladi M, Furman WL, Chin T, Freeman B, Stewart CF, Krailo M, Houghton PJ, Wright J, Adamson P, Blaney SC. A Phase I trial and pharmacokinetic study of depsipeptide in pediatric patients with refractory solid tumors: A Children’s Oncology Group Study. American Society of Clinical Oncology, 2005.
Books
Fouladi M. The Hospital for Sick Children Handbook of Pediatrics. In: Dipchand AI, ed. Oncology, 9th Edition, 1997.
Invited Paper, "Complications in long-term survivors of childhood cancer." ASCO Educational Book, 2004.
